COMIRNATY
Commercial- Indications
- COVID-19
Company intelligence / Profile preview
Acuitas Therapeutics
Vancouver, British Columbia, Canadaacuitastx.com ↗
- Ownership
- Private
- Employees
- ~74
- Development stage
- Commercial
01
Overview
Acuitas’ LNP platform has enabled two approved products—ONPATTRO® for transthyretin amyloidosis and COMIRNATY®, the Pfizer-BioNTech COVID‑19 vaccine. Over the past two years alone, their technology has supported at least twenty-six clinical trials initiated by partners. The company continues to expand applications of its platform into infectious diseases and oncology through collaborations.
- Therapeutic areas
- GastroenterologyHematologyRare DiseasesInfectious Diseases
- Modalities
- Lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics, including mRNA, siRNA, and DNA
- Industry
- Drug Discovery Services
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Pfizer/BioNTech – for COMIRNATY®, the leading global COVID‑19 vaccine using Acuitas’ LNP techAlnylam Pharmaceuticals – for ONPATTRO®, first RNAi therapeutic using their LNPCureVac – development agreement on encapsulated mRNAs
Beyond the preview
Go deeper on Acuitas Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Acuitas Therapeutics.